Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient

Yang,Shaoyu; Wu,Liming; Li,Xin; Huang,Jie; Zhong,Jianbo; Chen,Xueqin

doi:10.3892/mco.2018.1553

Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient

Authors:
- Shaoyu Yang
- Liming Wu
- Xin Li
- Jie Huang
- Jianbo Zhong
- Xueqin Chen
View Affiliations

Affiliations: Department of Medical Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China, Department of Dermatology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: January 11, 2018 https://doi.org/10.3892/mco.2018.1553
Pages: 457-459

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Crizotinib is an oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK) tyrosine‑kinase that has been approved for treating patients with advanced echinoderm microtubule associated protein like 4‑ALK rearranged non‑small‑cell lung cancer (NSCLC). Toxic epidermal necrolysis (TEN) is a rare adverse event associated with crizotinib. The present study reported a case of a 75‑year‑old Chinese male patient with advanced NSCLC with ALK fusion, who developed TEN after 56 days of crizotinib treatment and demised due to this dermatological adverse event. The occurrence of severe cutaneous necrolysis that predominantly involves the skin and mucous membranes during crizotinib treatment should alert clinicians to be aware of TEN and take prompt actions.

View Figures

View References

1	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sawamura S, Kajihara I, Ichihara A, Fukushima S, Jinnin M, Yamaguchi E, Kohrogi H and Ihn H: Crizotinib-associated erythema multiforme in a lung cancer patient. Drug Discov Ther. 9:142–143. 2015. View Article : Google Scholar : PubMed/NCBI
3	Park J, Yoshida K, Kondo C, Shimizu J, Horio Y, Hijioka S and Hida T: Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib. Lung Cancer. 81:495–496. 2013. View Article : Google Scholar : PubMed/NCBI
4	Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M and Nakagawa K: Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol. 31:e15–e17. 2013. View Article : Google Scholar : PubMed/NCBI
5	Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, Ficker JH and Brueckl WM: Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer. 95:35–38. 2016. View Article : Google Scholar : PubMed/NCBI
6	Honda Y, Hattori Y, Katsura S, Terashima T, Manabe T, Otsuka A and Miyachi Y: Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib. Eur J Dermatol. 26:413–414. 2016.PubMed/NCBI
7	Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ and Lacouture ME: Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 25:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
8	Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA and Seminario-Vidal L: Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 44:381–384. 2017. View Article : Google Scholar : PubMed/NCBI
9	Collins LK, Chapman MS, Carter JB and Samie FH: Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 41:125–128. 2017. View Article : Google Scholar : PubMed/NCBI
10	Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR and Spoendlin J: The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 137:1240–1247. 2017. View Article : Google Scholar : PubMed/NCBI
11	Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS and Ng MH: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 48:1015–1018. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY and Chen YT: Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 428:4862004. View Article : Google Scholar : PubMed/NCBI